ClinicalTrials.gg
Enrolling by invitationNCT06456320Updated Nov 4, 2026

Mayo Clinic Tapestry 2.0: Applying Multi-Omics for Scientific Discovery

An observational study in Genetic Predisposition and Exposure, Environmental, sponsored by Mayo Clinic. Enrolling by invitation at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Mayo Clinic · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
10,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 87 studies in Genetic Predisposition to Disease with a site in United States — 37 open to participants now, 46 under way, none of them phase 3. Genetic Predisposition to Disease · United States.

Planned enrollment
5th of 50
10,000 · median 560
Started
2024
with 6 others
Observational
50 of 87
23 open now
Primary completion
2027-12
later than 21 of 45 live
Registered
72nd of 87
by date
Lead sponsor
4 of 87
Mayo Clinic

Among the 87 studies in Genetic Predisposition to Disease with a site in United States, this one is the 5th largest by planned enrollment of the 50 observational ones that give a count, is one of 7 that started in 2024, is one of 50 observational ones, reaches primary completion later than 21 of the 45 other live ones, and was the 72nd registered.

Genetic Predisposition to Disease

242 studies on the registry are indexed under Genetic Predisposition to Disease; 96 are open to participants now.

Browse Genetic Predisposition to Disease studies →

Open to participants now

37 of the 87 studies in Genetic Predisposition to Disease with a site in United States are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 71 Genetic Predisposition to Disease studies recruiting now, 36 (51%) set no upper age limit and 28 (39%) stop at 75 or younger; 25 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Genetic Predisposition to Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to use multi-omics testing on samples collected from Mayo Clinic patients to build and expand on what has been learned about genomic data.

03

Conditions studied

  • Genetic Predisposition
  • Exposure, Environmental
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Mayo Clinic patients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Registered Mayo Clinic patient
  • Able to provide informed written consent
  • Able to receive mail and packages within a United States (US) state
  • Able to collect and ship samples within a US state

Exclusion criteria

Exclusion Criteria:

  • Active hematological cancer or history of a hematological cancer
  • Bone Marrow Transplant (e.g., samples from autologous bone marrow transplant recipients are acceptable if collected at least one month after transplant)
  • Other co-morbidity that, in physician's opinion, would interfere with patient's ability to participate in the study (e.g., reduced ability to comprehend, i.e., dementia, intellectual disability, etc.)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
10,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Suspected Genetic Predisposition or Multi-Omics Contribution

    Patients with a diagnosis or phenotype with the potential for association with a genetic predisposition or Multi-Omics Contribution.

  • Healthy Control

    Patients with no diagnosis associated with a genetic predisposition or Multi-Omics Contribution.

06

What researchers measure

Primary outcomes

  1. Creation of a unique integrated asset of multi-omics data

    A variety of patient cohorts will be ascertained throughout this study. Data will be made available to researchers to query correlations of disease states and clinical outcomes to multi-omics findings. These insights will be invaluable to creating omics-informed care plans in the future. Standard descriptive statistics approaches will be used for analysis.

    Time frame: Up to 5 years

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Dec 2027, 39 months after the start.

Of 80 non-industry observational studies under Genetic Predisposition to Disease, half reached primary completion within 96 months of starting (the median), counting those still running; a quarter within 52. This study's planned 39 months is below that.

Counting every sponsor, half of 82 studies reached it within 96 months; a quarter within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2024
First posted
Jun 13, 2024
StartActual
Sep 5, 2024
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and oversight details
1 update, last Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Minor edits only
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06456320
Lead sponsor
Mayo Clinic
Responsible party
Konstantinos N. Lazaridis, M.D. (Executive Director, Center for Individualized Medicine, Mayo Clinic) — Principal investigator
First posted
Jun 13, 2024
Start date
Sep 5, 2024
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Konstantinos N. Lazaridis, M.D.
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion